JP2021112205A5 - - Google Patents

Download PDF

Info

Publication number
JP2021112205A5
JP2021112205A5 JP2021074634A JP2021074634A JP2021112205A5 JP 2021112205 A5 JP2021112205 A5 JP 2021112205A5 JP 2021074634 A JP2021074634 A JP 2021074634A JP 2021074634 A JP2021074634 A JP 2021074634A JP 2021112205 A5 JP2021112205 A5 JP 2021112205A5
Authority
JP
Japan
Prior art keywords
pairs
indicator
region
regions
standard deviation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021074634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021112205A (ja
JP7229297B2 (ja
Filing date
Publication date
Priority claimed from JP2017508488A external-priority patent/JP6877334B2/ja
Application filed filed Critical
Publication of JP2021112205A publication Critical patent/JP2021112205A/ja
Publication of JP2021112205A5 publication Critical patent/JP2021112205A5/ja
Priority to JP2022187930A priority Critical patent/JP7680995B2/ja
Application granted granted Critical
Publication of JP7229297B2 publication Critical patent/JP7229297B2/ja
Priority to JP2025078359A priority patent/JP2025114740A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021074634A 2014-08-15 2021-04-27 相同組換え欠損を評価するための方法および材料 Active JP7229297B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022187930A JP7680995B2 (ja) 2014-08-15 2022-11-25 相同組換え欠損を評価するための方法および材料
JP2025078359A JP2025114740A (ja) 2014-08-15 2025-05-09 相同組換え欠損を評価するための方法および材料

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462037764P 2014-08-15 2014-08-15
US62/037,764 2014-08-15
US201414507412A 2014-10-06 2014-10-06
US14/507,412 2014-10-06
JP2017508488A JP6877334B2 (ja) 2014-08-15 2015-08-17 相同組換え欠損を評価するための方法および材料

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017508488A Division JP6877334B2 (ja) 2014-08-15 2015-08-17 相同組換え欠損を評価するための方法および材料

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187930A Division JP7680995B2 (ja) 2014-08-15 2022-11-25 相同組換え欠損を評価するための方法および材料

Publications (3)

Publication Number Publication Date
JP2021112205A JP2021112205A (ja) 2021-08-05
JP2021112205A5 true JP2021112205A5 (https=) 2021-09-16
JP7229297B2 JP7229297B2 (ja) 2023-02-27

Family

ID=54035301

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017508488A Active JP6877334B2 (ja) 2014-08-15 2015-08-17 相同組換え欠損を評価するための方法および材料
JP2021074634A Active JP7229297B2 (ja) 2014-08-15 2021-04-27 相同組換え欠損を評価するための方法および材料
JP2022187930A Active JP7680995B2 (ja) 2014-08-15 2022-11-25 相同組換え欠損を評価するための方法および材料
JP2025078359A Pending JP2025114740A (ja) 2014-08-15 2025-05-09 相同組換え欠損を評価するための方法および材料

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017508488A Active JP6877334B2 (ja) 2014-08-15 2015-08-17 相同組換え欠損を評価するための方法および材料

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022187930A Active JP7680995B2 (ja) 2014-08-15 2022-11-25 相同組換え欠損を評価するための方法および材料
JP2025078359A Pending JP2025114740A (ja) 2014-08-15 2025-05-09 相同組換え欠損を評価するための方法および材料

Country Status (9)

Country Link
US (4) US10400287B2 (https=)
EP (4) EP3180447B1 (https=)
JP (4) JP6877334B2 (https=)
AU (2) AU2015301390B2 (https=)
CA (1) CA2958801A1 (https=)
DK (3) DK3686288T3 (https=)
ES (3) ES2946251T3 (https=)
PT (1) PT3180447T (https=)
WO (1) WO2016025958A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
EP3766986B1 (en) * 2014-12-31 2022-06-01 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
EP3423048A4 (en) * 2016-02-29 2019-10-23 Synta Pharmaceuticals Corp. COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER
WO2017178509A1 (en) * 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
EP3452937B1 (en) 2016-05-01 2025-10-22 Genome Research Limited Method of characterising a dna sample
JP7224185B2 (ja) 2016-05-01 2023-02-17 ゲノム・リサーチ・リミテッド Ｄｎａサンプルを特徴付ける方法
WO2018162439A1 (en) * 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN108663519A (zh) * 2017-04-21 2018-10-16 江苏希摩生物科技有限公司 快速预测和提高BRCA1/2野生型卵巢癌细胞对Olaparib敏感性的方法
WO2019079255A1 (en) * 2017-10-16 2019-04-25 Board Of Regents Of The University Of Texas System METHODS AND COMPOSITIONS FOR THE USE OF TREX2 AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER
US10975445B2 (en) 2019-02-12 2021-04-13 Tempus Labs, Inc. Integrated machine-learning framework to estimate homologous recombination deficiency
WO2021011507A1 (en) * 2019-07-12 2021-01-21 Tempus Labs Adaptive order fulfillment and tracking methods and systems
WO2021070039A2 (en) * 2019-10-09 2021-04-15 Immunitybio, Inc. Detecting homologous recombination deficiencies (hrd) in clinical samples
ES2989374T3 (es) 2019-12-10 2024-11-26 Tempus Ai Inc Sistemas y procedimientos para predecir el estado de deficiencia de recombinación homóloga de una muestra
JP7842700B2 (ja) * 2020-05-14 2026-04-08 ガーダント ヘルス， インコーポレイテッド 相同組換え修復欠損の検出
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
CN112397145A (zh) * 2020-11-19 2021-02-23 河南省肿瘤医院 一种基于芯片检测的hrd评分计算方法
JP7585015B2 (ja) 2020-12-04 2024-11-18 株式会社東芝 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法
US20240026462A1 (en) * 2021-01-10 2024-01-25 Ying Ja CHEN Homologous recombination deficiency determining method and kit thereof
WO2022150063A1 (en) * 2021-01-10 2022-07-14 Act Genomics (Ip) Co., Ltd. Homologous recombination deficiency determining method and kit thereof
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
CN112980834B (zh) * 2021-04-22 2021-08-17 菁良基因科技(深圳)有限公司 一种同源重组修复缺陷参考品及其制备方法和试剂盒
CN113257346B (zh) * 2021-06-28 2021-10-19 北京橡鑫生物科技有限公司 一种基于低深度WGS评估HRD score的方法
CN113658638B (zh) * 2021-08-20 2022-06-03 江苏先声医学诊断有限公司 一种基于ngs平台的同源重组缺陷的检测方法和质控体系
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
CN118369439A (zh) * 2021-12-08 2024-07-19 麦利亚德基因公司 用于评估乳腺癌亚型中同源重组缺陷的方法和材料
CN114242170B (zh) * 2021-12-21 2023-05-09 深圳吉因加医学检验实验室 一种同源重组修复缺陷的评估方法、装置和存储介质
CN114283889B (zh) * 2021-12-27 2024-12-10 深圳吉因加医学检验实验室 一种矫正同源重组修复缺陷评分的方法及装置
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
EP4605937A1 (en) 2022-10-19 2025-08-27 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
WO2025173014A1 (en) 2024-02-16 2025-08-21 Onecell Diagnostics India Private Limited A method for selecting ovarian cancer patients for parp inhibitor treatment

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3630497A1 (de) 1986-09-08 1988-03-10 Behringwerke Ag Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
DK252688A (da) 1987-05-08 1988-11-09 Sankyo Co Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse
US4996337A (en) 1987-06-23 1991-02-26 American Cyanamid Company Synthesis of cisplatin analogs
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5214821A (en) 1991-05-07 1993-06-01 The Morgan Crucible Company Plc Low contamination swab employing tubular knit fabric
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
ATE247471T1 (de) 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
WO1998041531A2 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
GB9808145D0 (en) 1998-04-17 1998-06-17 Zeneca Ltd Assay
WO2000009759A1 (en) 1998-08-17 2000-02-24 The Burnham Institute Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
US6534293B1 (en) 1999-01-06 2003-03-18 Cornell Research Foundation, Inc. Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
IL163600A0 (en) 2002-03-01 2005-12-18 Ravgen Inc Methods for detection of genetic disorders
AU2003291281A1 (en) 2002-11-01 2004-06-07 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US20070004621A1 (en) 2003-02-12 2007-01-04 Viji Shridhar Bex4 nucleic acids, polypeptides, and method of using
US20040170983A1 (en) 2003-02-27 2004-09-02 Danenberg Kathleen D. Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
WO2004083816A2 (en) 2003-03-14 2004-09-30 John Wayne Cancer Institute Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
CN100412084C (zh) 2003-07-02 2008-08-20 獀洛克斯股份有限公司 热稳定的结晶盐酸表柔比星及其制造方法
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
AU2004270655B2 (en) 2003-08-13 2011-03-24 University Of South Florida Methods for inhibiting tumor cell proliferation
US20080108057A1 (en) 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
US7860840B2 (en) 2004-10-05 2010-12-28 Microsoft Corporation Maintaining correct transaction results when transaction management configurations change
CA2584723A1 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
US20070070349A1 (en) 2005-09-23 2007-03-29 Helicos Biosciences Corporation Optical train and method for TIRF single molecule detection and analysis
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
ES2404311T3 (es) 2005-04-12 2013-05-27 454 Life Sciences Corporation Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda
WO2006116341A1 (en) 2005-04-21 2006-11-02 Alza Corporation Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
ATE488507T1 (de) 2005-06-30 2010-12-15 Bionumerik Pharmaceuticals Inc Platinanaloga mit monoazolligand
JP5477888B2 (ja) 2005-09-21 2014-04-23 バイオアレイ ソリューションズ リミテッド 単鎖プライマ−プロモータ−セレクタ構造とｉｖｔを用いたメッセージ発生量及び対立遺伝子コピー数の決定
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2134855A4 (en) 2007-03-12 2011-01-05 Dana Farber Cancer Inst Inc USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY
WO2009033178A1 (en) 2007-09-07 2009-03-12 Fluidigm Corporation Copy number variation determination, methods and systems
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
RU2010128107A (ru) 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
US20090246789A1 (en) 2008-03-25 2009-10-01 University Of South Carolina Gene Mutation Profiling of CSMD1
WO2009148528A2 (en) 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
JP5570516B2 (ja) 2008-10-31 2014-08-13 アッヴィ・インコーポレイテッド 遺伝子コピー数の変化のパターンに基づいた結腸直腸癌のゲノム分類
US10262103B2 (en) 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
US8206910B2 (en) 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
KR100925337B1 (ko) 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
EP2491139A1 (en) 2009-10-19 2012-08-29 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
CA2798657A1 (en) 2010-02-24 2011-09-01 Alexander Gutin Diagnostic methods involving loss of heterozygosity
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012019000A2 (en) 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
KR102759126B1 (ko) 2010-12-30 2025-01-24 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
CA2864481C (en) * 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
AU2014248007B2 (en) * 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CN105917007A (zh) 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途

Similar Documents

Publication Publication Date Title
JP2021112205A5 (https=)
JP2016523511A5 (https=)
Lothe et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history
Morsani et al. Genetic predisposition to persistent apical periodontitis
ES2946251T3 (es) Métodos y materiales para evaluar la deficiencia de recombinación homóloga
Ladetto et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
McCall et al. Symptom experience, management, and outcomes according to race and social determinants including genomics, epigenomics, and metabolomics (SEMOARS+ GEM): an explanatory model for breast cancer treatment disparity
Barroilhet et al. The NCI-MATCH trial and precision medicine in gynecologic cancers
Dill et al. Analysis of multiple cytokine polymorphisms in individuals with untreated deep carious lesions reveals IL1B (rs1143643) as a susceptibility factor for periapical lesion development
Otsuka et al. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil–oteracil potassium in metastatic and recurrent breast cancer
Machover et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma
Cai et al. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial
Machado et al. Postoperative pain after single-visit root canal treatments in necrotic teeth comparing instruments’ kinematics and apical instrumentation limits–a prospective randomized multicenter clinical trial
Cahuayme-Zuniga et al. Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies
Yagita et al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.
Yin et al. A phase II trial of the double epigenetic priming regimen including chidamide and decitabine for relapsed/refractory acute myeloid leukemia
Riera et al. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients
Ladeira et al. Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring
Costa de Sousa et al. Polysacharide of Agaricus blazei gel mitigates bone necrosis in model of the jaws related to bisphosphonate via Wnt signaling
Nakamura et al. Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer
Hannum et al. Lack of association between IL-10-1082G/A polymorphism and chronic periodontal disease in adults
Chauhan et al. Association of genetic polymorphism of interleukin 1-alpha and interleukin 1-beta with external apical root resorption in orthodontic patients
Kawai et al. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients
CN104419759A (zh) 肺癌易感基因的单核苷酸多态性位点rs7975232的检测方法及检测试剂盒
CN115667552A (zh) 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷